Limonene can reduce the anxiety sometimes felt when using cannabis

A recent study funded by the National Institute on Drug Abuse (NIDA) has highlighted the potential of the D-limonene, a terpene found in cannabis and various citrus fruits, to mitigate certain negative effects of the THC (tetrahydrocannabinol), the main psychoactive component of cannabis.

This study, detailed in Drug and Alcohol Dependence, revealed promising results suggesting that the D-limonene (also known as limonene) could significantly reduce THC-induced feelings of anxiety and paranoia when administered at the same time.

The Role of D-Limonene in Reducing Anxiety

According to the study, participants who sprayed D-limonene who also used THC reported a reduced levels of anxiety and paranoia compared to those who consumed THC alone. The report notes that «subjective effects similar to anxiety decrease qualitatively as the dose of D-limonene increases.».

Research also contributes to our understanding of the’cannabis entourage effect, a theory according to which various compounds in the plant interact synergistically to modulate its effects. The study’s authors, from various institutions such as the Johns Hopkins University School of Medicine and theUniversity of Colorado Anschutz Medical Campus, suggest that the D-limonene illustrates this phenomenon by selectively reducing THC-induced anxiety, thereby broadening the therapeutic index of cannabis.

Implications for Medical Treatment and Public Health

The implications of these findings could be useful for certain medical uses of cannabis and for public health initiatives more broadly. By identifying specific components such as the D-limonene that can improve the safety profile of cannabis, researchers aim to advance the development of cannabinoid-based medications more effective and safer. This could lead to the development of new formulations of cannabis-based products designed to maximize therapeutic benefits while minimizing adverse effects.

The study’s authors emphasize the need for further rigorous clinical studies to build on these findings. They suggest that the development of cannabis products enriched with D-limonene could be a simple strategy for broadening the therapeutic window of medical cannabis, from THC and terpenes, potentially reducing the risks associated with the nonmedical use of cannabis.